arcusbio.com (RCUS): Price-to-Projected Revenue Ratio

RCUS (Arcus Biosciences Inc) - company brandmark

Arcus Biosciences, Inc. (RCUS) is protected by molecule patents and its alliance with Gilead, while stringent FDA oversight eliminates smaller players. However, reagent supply chain disruptions and trade disputes complicate global expansion. The company is developing advanced antibody combinations to combat tumor masking. P/S expectations for the company reflect valuation volatility, with the value fixed at 22.30.

RCUS Arcus Biosciences Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Arcus Biosciences, Inc. (RCUS)

- stock price and consensus target price:
Stock Quotes Arcus Biosciences Inc|RCUS - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Arcus Bio|RCUS - Business Value
- book value of equity indicators:
Net Assets per Single Share Arcus Biosciences|RCUS - Total Stockholders' Equity|Market Cap to Net Assets Ratio arcusbio.com|RCUS - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Arcus Biosciences, Inc.|RCUS - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Arcus Biosciences|RCUS - Aggregate Debt Obligations|Debts to Book Capitalization Arcus Corp|RCUS - Long-Term Debt|Company Short-Term Debt Arcus Biosciences|Quick Ratio arcusbio.com
- business earnings and investment ratios data:
RCUS - Net Profit|Expected Profit Arcus Biosciences, Inc.|RCUS - Market Cap to Net Income|Projected Price to Earnings Arcus Biosciences Inc|RCUS - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Arcus Biosciences|RCUS - Operating profit EBITDA|Earnings per share for the last twelve months Arcus Biosciences|RCUS - Earnings per share for the trailing year|Quarterly EPS earnings growth arcusbio.com|RCUS - Net earnings per share growth this year|Expected earnings per share growth for next year Arcus Biosciences, Inc.
- revenue and sales details:
RCUS - Revenue and Sales Volume|Company Projected Revenue Arcus Corp|RCUS - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Arcus Biosciences Inc
Summary company analysis:arcusbio.com RCUS
Manufactured products of Arcus Corp

Arcus Biosciences, Inc. (RCUS) commitment to bioethics and data transparency drives the long-term value of its developments. Analyzing this value via the forward P/S metric allows for a comparison of current market capitalization against projected revenue for the coming year. This indicator reveals abnormal volatility and assesses the sustainability of the price trend relative to expected cash flows. This tool is indispensable for risk assessment within the high-tech biopharmaceutical sector.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|ZYME (zymeworks.com) - Market Cap to Projected Revenue|Tango Therapeutics Corp (TNGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Iovance (IOVA)|Forward Price-to-Revenue Multiple IMTX|XNCR - Projected Price to Revenue|Forward Price-to-Revenue Multiple CMPX (Compass Bio)|Price to Expected Revenue Ratio REPL|Forward P/S Multiple LYEL (Lyell Immunopharma, Inc.)|Forward Price to Sales IPHA|Pyxis - Forward P/S Multiple|Market Cap to Future Revenue Ratio Compugen|IO Biotech, Inc. (IOBT) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc. - Forward Price to Sales|INKT (minktherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple werewolftx.com|Price-to-Projected Revenue Ratio immixbio.com (IMMX)|ALXO: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP